Home › Funds › Paradigm Biocapital Advisors LP › GMAB

Paradigm Biocapital Advisors LP position in GMAB

GENMAB A/S · Health Care

Paradigm Biocapital Advisors LP reported holding 14,136,472 shares of GMAB (GENMAB A/S) in its Q3 2026 13F filing — a position valued at US$504.3M, representing 10.03% of its reported portfolio and ranking #2 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed GMAB holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)14.14M sh
Reported value held$504.32M
Portfolio Weight10.03%
First reportedQ3 2025
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's GMAB position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in GMAB in Q3 2025 at 3,816,851 shares (US$117.1M). The position peaked in Q3 2026 at 14,136,472 shares, worth US$504.3M. Across 5 filings, Paradigm Biocapital Advisors LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 14,136,472 shares valued at US$504.3M — an increase of 1,003,341 shares quarter over quarter.. Notable position changes include a 84% increase in Q4 2025 (shares fell 13% over the following quarter), a 65% increase in Q2 2026 (shares rose 30% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 3.82M $117.06M New
Q4 2025 7.04M $216.83M Add
Q1 2026 7.97M $213.78M Add
Q2 2026 13.13M $360.77M Add
Q3 2026 14.14M $504.32M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GMAB and 13F data

GMAB (GENMAB A/S) is a Health Care company. 36 other funds we track also report a position in GMAB — the largest reported positions include Orbis Allan Gray Ltd (US$377.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$188.6M), Sofinnova Investments, Inc. (US$155.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GMAB

All GMAB fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held GMAB?

Paradigm Biocapital Advisors LP has disclosed GMAB holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Paradigm Biocapital Advisors LP's current position in GMAB?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 14.14M shares of GMAB (GENMAB A/S), valued at $504.32M, representing 10.03% of its reported portfolio and ranking #2.

Has Paradigm Biocapital Advisors LP been buying or selling GMAB?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in GMAB. The position peaked in Q3 2026 at 14.14M shares.

Which other funds hold GMAB?

Other major institutional holders of GMAB include Orbis Allan Gray Ltd, DEERFIELD MANAGEMENT COMPANY, L.P., Sofinnova Investments, Inc., among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.